|
BY ORDER OF THE BOARD
/s/ Margaret Henry
Margaret Henry
Company Secretary April [ ], 2023 |
| |
Registered Office
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX, United Kingdom Registered in England and Wales No 09338148 |
|
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 10 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 15 | | | |
| | | | 17 | | | |
| | | | 18 | | | |
| | | | 19 | | | |
| | | | 27 | | | |
| | | | 30 | | | |
| | | | 31 | | | |
| | | | 32 | | | |
| | | | 35 | | | |
| | | | 37 | | | |
| | | | 55 | | | |
| | | | 73 | | | |
| | | | 74 | | | |
| | | | 75 | | | |
| | | | A-1 | | | |
| | | | A-28 | | |
|
Proposal
|
| |
Description of Proposal
|
| |
Board’s
Recommendation |
|
|
1
|
| | Re-election of Adrian Rawcliffe as a director | | |
FOR
|
|
|
2
|
| | Re-election of Barbara Duncan as a director | | |
FOR
|
|
|
3
|
| | Re-appointment of KPMG LLP as the Company’s auditors, to hold office until the conclusion of the next annual general meeting of shareholders | | |
FOR
|
|
|
4
|
| | Authorization for the Audit Committee to determine our auditors’ remuneration for the fiscal year ending December 31, 2023 | | |
FOR
|
|
|
5
|
| | To adopt the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 | | |
FOR
|
|
|
6
|
| | Approval of the compensation of our named executive officers for the year ended December 31, 2022, which is set forth in this proxy statement | | |
FOR
|
|
|
7
|
| | Approval of our U.K. statutory directors’ annual report on remuneration for the year ended December 31, 2022 (excluding our directors’ remuneration policy), which is set forth as Annex A | | |
FOR
|
|
|
8
|
| | Authorization for the Board of Directors to allot shares or to grant rights to subscribe for or convert any security into shares up to a maximum aggregate nominal amount of £327,921.00 | | |
FOR
|
|
|
9
|
| | Empowering the Board of Directors to allot equity securities for cash up to a maximum aggregate nominal amount of £327,921.00 pursuant to the authorization in Proposal No. 8 as if U.K. statutory pre-emption rights did not apply. | | |
FOR
|
|
Fees
|
| |
December 31, 2022
($) |
| |
December 31, 2021
($) |
| ||||||
Audit Fees(1)
|
| | | | 1,374,000 | | | | | | 1,218,000 | | |
Audit-related Fees(2)
|
| | | | 72,000 | | | | | | 91,000 | | |
Tax Fees(3)
|
| | | | — | | | | | | — | | |
All Other Fees(4)
|
| | | | — | | | | | | — | | |
Total | | | | | 1,446,000 | | | | | | 1,309,000 | | |
Name
|
| |
Age
|
| |
Position
|
|
David M. Mott | | |
57
|
| | Chairman of the Board of Directors | |
Lawrence M. Alleva | | |
73
|
| | Non-Executive Director | |
Ali Behbahani, M.D. | | |
46
|
| | Non-Executive Director | |
Barbara Duncan | | |
58
|
| | Non-Executive Director | |
John Furey | | |
58
|
| | Non-Executive Director | |
James Noble. | | |
64
|
| | Non-Executive Director | |
Elliott Sigal, Ph.D, M.D. | | |
71
|
| | Non-Executive Director | |
Adrian Rawcliffe | | |
51
|
| | Chief Executive Officer and Director | |
|
Board Diversity Matrix
|
| ||||||||||||
| Country of Principal Executive Offices: | | |
England
|
| |||||||||
| Foreign Private Issuer | | |
No
|
| |||||||||
| Disclosure Prohibited under Home Country Law | | |
No
|
| |||||||||
| Total Number of Directors | | |
8
|
|
| | |
Female
|
| |
Male
|
| |
Non-Binary
|
| |
Did Not
Disclose Gender |
|
Part I: Gender Identity | | | | | | | | | | | | | |
Directors | | |
1
|
| |
7
|
| |
0
|
| |
0
|
|
Part II: Demographic Background | | | | | | | | | | | | | |
Underrepresented Individual in Home Country Jurisdiction | | |
1
|
| | | | | | | | | |
LGBTQ+ | | |
0
|
| | | | | | | | | |
Did Not Disclose Demographic Background | | |
0
|
| | | | | | | | | |
Name
|
| |
Audit
|
| |
Remuneration
|
| |
Corporate
Governance and Nominating |
|
David M. Mott | | | | | |
Chair
|
| |
Chair
|
|
Lawrence M. Alleva | | |
Chair
|
| | | | | | |
Ali Behbahani, M.D. | | | | | | | | |
X
|
|
Barbara Duncan | | |
X
|
| | | | | | |
John Furey | | |
X
|
| |
X
|
| | | |
Elliott Sigal, Ph.D, M.D. | | | | | | | | |
X
|
|
| | |
Ordinary Shares
Beneficially Owned |
| |||||||||
Name of Beneficial Owner
|
| |
Number
|
| |
Percent
|
| ||||||
5% Shareholders | | | | | | | | | | | | | |
Matrix Capital Management Master Fund L.P(1)
|
| | | | 233,845,110 | | | | | | 23.53 | | |
Baillie Gifford & Co(2)
|
| | | | 103,019,634 | | | | | | 10.37 | | |
New Enterprise Associates(3)
|
| | | | 102,478,672 | | | | | | 10.31 | | |
Baker Bros. Advisors, L.P.(4)
|
| | | | 58,985,262 | | | | | | 5.94 | | |
Named Executive Officers and Directors | | | | | | | | | | | | | |
Adrian Rawcliffe(5)
|
| | | | 15,656,150 | | | | | | 1.58 | | |
William Bertrand(6)
|
| | | | 7,901,234 | | | | | | * | | |
Gavin Wood(7)
|
| | | | 3,801,734 | | | | | | * | | |
Elliot Norry, M.D.(8)
|
| | | | 2,505,900 | | | | | | * | | |
Cintia Piccina(9)
|
| | | | 1,451,802 | | | | | | * | | |
Ali Behbahani, M.D.(10)
|
| | | | 104,087,563 | | | | | | 10.47 | | |
James Noble(11)
|
| | | | 17,843,233 | | | | | | 1.80 | | |
Elliott Sigal, M.D., Ph.D.(12)
|
| | | | 2,364,324 | | | | | | * | | |
Lawrence M. Alleva(13)
|
| | | | 2,232,797 | | | | | | * | | |
David M. Mott(14)
|
| | | | 2,001,724 | | | | | | * | | |
Barbara Duncan(15)
|
| | | | 1,367,562 | | | | | | * | | |
John Furey(16)
|
| | | | 1,100,748 | | | | | | * | | |
Executive Officers | | | | | | | | | | | | | |
Helen Tayton-Martin, Ph.D.(17)
|
| | | | 11,197,200 | | | | | | 1.13 | | |
John Lunger(18)
|
| | | | 4,391,025 | | | | | | * | | |
Joanna Brewer, Ph.D(19)
|
| | | | 1,733,762 | | | | | | * | | |
Named Executive Officers, Directors and Executives as a Group (15 persons)
|
| | | | 179,636,758 | | | | | | 18.08 | | |
| | |
2022 Cash
Compensation |
| |||
Board of Directors
|
| | | $ | 40,000 | | |
Chairman (additional retainer)
|
| | | $ | 30,000 | | |
Audit Committee Chair (additional retainer)
|
| | | $ | 20,000 | | |
Remuneration Committee Chair (additional retainer)
|
| | | $ | 15,000 | | |
Corporate Governance and Nominating Committee Chair (additional retainer)
|
| | | $ | 10,000 | | |
Audit Committee member/non-Chair (additional retainer)
|
| | | $ | 10,000 | | |
Remuneration Committee member/non-Chair (additional retainer)
|
| | | $ | 7,500 | | |
Corporate Governance and Nominating Committee member/non-Chair (additional retainer)
|
| | | $ | 5,000 | | |
Name
|
| |
Fees Earned
or paid in cash$(1) |
| |
Option
awards($)(2) |
| |
Total ($)
|
| |||||||||
David M. Mott(3)
|
| | | | — | | | | | | 208,542 | | | | | | 208,542 | | |
Lawrence Alleva(4)
|
| | | | — | | | | | | 170,109 | | | | | | 170,109 | | |
Ali Behbahani(5)
|
| | | | — | | | | | | 153,638 | | | | | | 153,638 | | |
Barbara Duncan(6)
|
| | | | 50,000 | | | | | | 104,225 | | | | | | 154,225 | | |
John Furey(7)
|
| | | | 57,500 | | | | | | 104,225 | | | | | | 161,725 | | |
James Noble(8)
|
| | | | 17,532 | | | | | | 148,148 | | | | | | 165,680 | | |
Elliott Sigal(9)
|
| | | | — | | | | | | 153,638 | | | | | | 153,638 | | |
Tal Zaks(10)
|
| | | | 47,500 | | | | | | 104,225 | | | | | | 151,725 | | |
Name
|
| |
Age
|
| |
Position
|
|
Adrian Rawcliffe | | |
51
|
| | Chief Executive Officer and Director | |
Gavin Wood | | |
53
|
| | Chief Financial Officer | |
Helen Tayton-Martin, Ph.D | | |
56
|
| | Chief Business & Strategy Officer | |
William Bertrand | | |
58
|
| | Chief Operating Officer | |
John Lunger | | |
54
|
| | Chief Patient Supply Officer | |
Elliot Norry, M.D | | |
60
|
| | Chief Medical Officer | |
Joanna Brewer, Ph.D | | |
47
|
| | Chief Scientific Officer | |
|
2022/2023
|
| |
2021/2022
|
|
|
Achilles Therapeutics plc
|
| |
Agenus Inc.
|
|
|
Agenus Inc.
|
| |
Atara Biotherapeutics, Inc
|
|
|
Atara Biotherapeutics, Inc
|
| |
Athenex, Inc.
|
|
|
Autolus Therapeutics plc
|
| |
Autolus Therapeutics plc
|
|
|
Bicycle Therapeutics plc
|
| |
bluebird bio, Inc.
|
|
|
bluebird bio, Inc.
|
| |
Clovis Oncology, Inc.
|
|
|
Immunocore Holding plc
|
| |
Dynavax Technologies Corporation
|
|
|
ImmunoGen, Inc
|
| |
Immunocore Holdings plc.
|
|
|
Inovio Pharmaceuticals, Inc.
|
| |
ImmunoGen, Inc
|
|
|
Instil Bio, Inc.
|
| |
Inovio Pharmaceuticals, Inc.
|
|
|
MacroGenics, Inc.
|
| |
MacroGenics, Inc..
|
|
|
Nkarta, Inc.
|
| |
Oxford Biomedica plc
|
|
|
Oxford Biomedica plc
|
| |
Poseida Therapeutics, Inc.
|
|
|
Poseida Therapeutics, Inc.
|
| |
Precigen, Inc.
|
|
|
Precigen, Inc.
|
| |
Precision Biosciences, Inc.
|
|
|
Precision Biosciences, Inc.
|
| |
Sangamo Therapeutics, Inc.
|
|
|
Replimune Group, Inc.
|
| |
Sorrento Therapeutics, Inc.
|
|
|
Sana Biotechnology, Inc.
|
| |
TCR2 Therapeutics, Inc.
|
|
|
Sangamo Therapeutics, Inc.
|
| | | |
|
TCR2 Therapeutics, Inc.
|
| | | |
Name
|
| |
2022 Annual
Base Salary ($) |
| |
2021 Annual
Base Salary ($) |
| |
% Increase
|
| |||||||||
Adrian Rawcliffe
|
| | | | 650,000 | | | | | | 617,050 | | | | | | 5.3% | | |
Gavin Wood(1)
|
| | | | 419,618 | | | | | | 409,384 | | | | | | 2.5% | | |
William Bertrand
|
| | | | 468,179 | | | | | | 456,760 | | | | | | 2.5% | | |
Elliot Norry
|
| | | | 446,355 | | | | | | 425,100 | | | | | | 5.0% | | |
Cintia Piccina(2)
|
| | | | 445,000 | | | | | | — | | | | | | — | | |
Name
|
| |
2022 Target
Annual Cash Bonus Opportunity % |
| |
2022 Target
Annual Cash Bonus Opportunity ($) |
| ||||||
Adrian Rawcliffe
|
| | | | 60% | | | | | | 390,000 | | |
Gavin Wood(1)
|
| | | | 45% | | | | | | 188,828 | | |
William Bertrand
|
| | | | 45% | | | | | | 210,681 | | |
Name
|
| |
2022 Target
Annual Cash Bonus Opportunity % |
| |
2022 Target
Annual Cash Bonus Opportunity ($) |
| ||||||
Elliot Norry
|
| | | | 45% | | | | | | 200,860 | | |
Cintia Piccina(2)
|
| | | | 45% | | | | | | 183,563 | | |
Name
|
| |
2022 Target
Annual Cash Bonus Opportunity ($) |
| |
2022 Calculated
Cash Bonus Payment (Based on 60% Performance) ($) |
| |
2022 Actual
Annual Cash Bonus Payment ($) |
| |||||||||
Adrian Rawcliffe
|
| | | | 390,000 | | | | | | 234,000 | | | | | | — | | |
Gavin Wood(1)
|
| | | | 188,828 | | | | | | 113,297 | | | | | | 56,648 | | |
William Bertrand
|
| | | | 210,681 | | | | | | 126,409 | | | | | | 63,204 | | |
Elliot Norry
|
| | | | 200,860 | | | | | | 120,516 | | | | | | 60,258 | | |
Cintia Piccina(2)
|
| | | | 183,563 | | | | | | 110,138 | | | | | | 55,069 | | |
Named Executive Officer
|
| |
Options for
ordinary shares (#) |
| |
RSU-Style
Options for ordinary shares (#) |
| |
Equity Awards
(Aggregate Grant Date Fair Value) ($) |
| |||||||||
Adrian Rawcliffe
|
| | | | 4,690,224 | | | | | | 1,047,480 | | | | | | 2,714,882 | | |
Gavin Wood
|
| | | | 1,407,072 | | | | | | 314,256 | | | | | | 814,474 | | |
William Bertrand
|
| | | | 1,407,072 | | | | | | 314,256 | | | | | | 814,474 | | |
Elliot Norry
|
| | | | 2,110,608 | | | | | | 471,360 | | | | | | 1,221,696 | | |
Cintia Piccina
|
| | | | 3,376,992 | | | | | | 1,089,384 | | | | | | 1,588,155 | | |
| | |
Ordinary Shares Beneficially
Owned as of December 31, 2021 |
| ||||||
Named Executive Officer
|
| |
Number(1)
|
| |
Value(2)
|
| |||
Adrian Rawcliffe
|
| | | | 557,646 | | | |
0.21 x base salary
|
|
Gavin Wood
|
| | | | 439,178 | | | |
0.25 x base salary
|
|
William Bertrand
|
| | | | 526,419 | | | |
0.27 x base salary
|
|
Elliot Norry
|
| | | | 137,850 | | | |
0.08 x base salary
|
|
Cintia Piccina
|
| | | | 208,944 | | | |
1.11 x base salary
|
|
| | | | The Remuneration Committee of the Board of Directors | |
| | | |
David M. Mott, Chairman
John Furey |
|
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Option
awards ($)(3) |
| |
Non-equity
incentive plan compensation ($)(4) |
| |
Bonus
($) |
| |
All other
compensation ($) |
| |
Total
($) |
| |||||||||||||||||||||
Adrian Rawcliffe(1)
Chief Executive Officer
|
| | | | 2022 | | | | | | 650,000 | | | | | | 2,714,882 | | | | | | — | | | | | | | | | | | | 43,645(5) | | | | | | 3,408,527 | | |
| | | 2021 | | | | | | 617,050 | | | | | | 3,207,291 | | | | | | 351,719 | | | | | | | | | | | | 38,941(6) | | | | | | 4,215,001 | | | ||
| | | 2020 | | | | | | 574,000 | | | | | | 1,715,346 | | | | | | 378,840 | | | | | | | | | | | | 33,416(7) | | | | | | 2,701,602 | | | ||
Gavin Wood(2)
Chief Financial Officer
|
| | | | 2022 | | | | | | 419,618 | | | | | | 814,474 | | | | | | 56,648 | | | | | | | | | | | | 31,955(8) | | | | | | 1,322,695 | | |
| | | 2021 | | | | | | 409,384 | | | | | | 1,069,101 | | | | | | 175,012 | | | | | | | | | | | | 31,598(9) | | | | | | 1,685,094 | | | ||
| | | 2020 | | | | | | 299,549(10) | | | | | | 990,268 | | | | | | 148,276 | | | | | | 42,361(11) | | | | | | 23,164(12) | | | | | | 1,503,618 | | | ||
William Bertrand
Chief Operating Officer
|
| | | | 2022 | | | | | | 468,179 | | | | | | 814,474 | | | | | | 63,204 | | | | | | | | | | | | 42,415(13) | | | | | | 1,388,271 | | |
| | | 2021 | | | | | | 456,760 | | | | | | 1,069,101 | | | | | | 195,265 | | | | | | | | | | | | 35,062(14) | | | | | | 1,756,188 | | | ||
| | | 2020 | | | | | | 443,456 | | | | | | 857,661 | | | | | | 219,511 | | | | | | | | | | | | 30,485(15) | | | | | | 1,551,113 | | | ||
Elliot Norry
Chief Medical Officer
|
| | | | 2022 | | | | | | 446,355 | | | | | | 1,221,696 | | | | | | 60,258 | | | | | | | | | | | | 42,436(16) | | | | | | 1,770,746 | | |
| | | 2021 | | | | | | 425,100 | | | | | | 1,069,101 | | | | | | 181,730 | | | | | | | | | | | | 35,062(17) | | | | | | 1,710,993 | | | ||
| | | 2020 | | | | | | 390,000 | | | | | | 204,881 | | | | | | 160,119 | | | | | | 117,000(18) | | | | | | 33,650(19) | | | | | | 905,650 | | | ||
Cintia Piccina
Chief Commmercial Officer
|
| | | | 2022 | | | | | | 407,917(20) | | | | | | 1,588,155 | | | | | | 55,069 | | | | | | 100,000(21) | | | | | | 34,454(22) | | | | | | 2,185,595 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Name
|
| |
First date some
or all options are exercisable(1) |
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable(2) |
| |
Number of
Securities Underlying Unexercised Options(#) Unexercisable(2) |
| |
Option
Exercise Price ($/Sh)(3) |
| |
Option
Expiration Date |
| |||||||||||||||
Adrian Rawcliffe
|
| | | | 03/16/2016(4) | | | | | | 3,000,000 | | | | | | 0 | | | | | | 0.61 | | | | | | 03/16/2025 | | |
| | | 01/18/2017(4) | | | | | | 939,948 | | | | | | 0 | | | | | | 1.08 | | | | | | 01/18/2026 | | | ||
| | | 01/13/2018(4) | | | | | | 2,072,976 | | | | | | 0 | | | | | | 0.71 | | | | | | 01/13/2027 | | | ||
| | | 01/12/2019(4) | | | | | | 687,984 | | | | | | 0 | | | | | | 1.16 | | | | | | 01/12/2028 | | | ||
| | | 01/04/2020 | | | | | | 0 | | | | | | 70,224 | | | | | | 0.0012 | | | | | | 01/04/2029 | | | ||
| | | 01/04/2020 | | | | | | 1,231,541 | | | | | | 26,203 | | | | | | 0.85 | | | | | | 01/04/2029 | | | ||
| | | 06/27/2020 | | | | | | 0 | | | | | | 35,112 | | | | | | 0.0012 | | | | | | 06/27/2029 | | | ||
| | | 06/27/2020 | | | | | | 550,248 | | | | | | 78,624 | | | | | | 0.64 | | | | | | 06/27/2029 | | | ||
| | | 09/01/2020 | | | | | | 0 | | | | | | 35,112 | | | | | | 0.0012 | | | | | | 09/01/2029 | | | ||
| | | 09/01/2020 | | | | | | 510,945 | | | | | | 117,927 | | | | | | 0.27 | | | | | | 09/01/2029 | | | ||
| | | 01/16/2021 | | | | | | 1,834,245 | | | | | | 681,291 | | | | | | 0.69 | | | | | | 01/16/2030 | | | ||
| | | 01/16/2021 | | | | | | 0 | | | | | | 280,896 | | | | | | 0.0012 | | | | | | 01/16/2030 | | | ||
| | | 01/11/2022 | | | | | | 0 | | | | | | 546,120 | | | | | | 0.0012 | | | | | | 01/11/2031 | | | ||
| | | 01/11/2022 | | | | | | 1,562,275 | | | | | | 1,698,125 | | | | | | 0.92 | | | | | | 01/11/2031 | | | ||
| | | 01/12/2023 | | | | | | 0 | | | | | | 1,047,480 | | | | | | 0.0012 | | | | | | 01/12/2032 | | | ||
| | | 01/12/2023 | | | | | | 0 | | | | | | 4,690,224 | | | | | | 0.53 | | | | | | 01/12/2032 | | | ||
Gavin Wood
|
| | | | 04/01/2021 | | | | | | 1,666,600 | | | | | | 833,400 | | | | | | 0.44 | | | | | | 04/01/2030 | | |
| | | 04/01/2021 | | | | | | 282,500 | | | | | | 282,500 | | | | | | 0.0012 | | | | | | 04/01/2030 | | | ||
| | | 01/11/2022 | | | | | | 60,678 | | | | | | 182,034 | | | | | | 0.0012 | | | | | | 01/11/2031 | | | ||
| | | 01/11/2022 | | | | | | 520,766 | | | | | | 566,050 | | | | | | 0.92 | | | | | | 01/11/2031 | | | ||
| | | 01/12/2023 | | | | | | 0 | | | | | | 314,256 | | | | | | 0.0012 | | | | | | 01/12/2032 | | | ||
| | | 01/12/2023 | | | | | | 0 | | | | | | 1,407,072 | | | | | | 0.53 | | | | | | 01/12/2032 | | | ||
William Bertrand
|
| | | | 03/15/2018(4) | | | | | | 3,407,904 | | | | | | 0 | | | | | | 0.79 | | | | | | 03/15/2027 | | |
| | | 01/12/2019(4) | | | | | | 644,976 | | | | | | 0 | | | | | | 1.16 | | | | | | 01/12/2028 | | | ||
| | | 01/04/2020 | | | | | | 0 | | | | | | 56,190 | | | | | | 0.0012 | | | | | | 01/04/2029 | | | ||
| | | 01/04/2020 | | | | | | 985,261 | | | | | | 20,963 | | | | | | 0.85 | | | | | | 01/04/2029 | | | ||
| | | 01/16/2021 | | | | | | 917,105 | | | | | | 340,639 | | | | | | 0.69 | | | | | | 01/16/2030 | | | ||
| | | 01/16/2021 | | | | | | 0 | | | | | | 140,448 | | | | | | 0.0012 | | | | | | 01/16/2030 | | | ||
| | | 01/11/2022 | | | | | | 0 | | | | | | 182,034 | | | | | | 0.0012 | | | | | | 01/11/2031 | | | ||
| | | 01/11/2022 | | | | | | 520,766 | | | | | | 566,050 | | | | | | 0.92 | | | | | | 01/11/2031 | | | ||
| | | 01/12/2023 | | | | | | 0 | | | | | | 314,256 | | | | | | 0.0012 | | | | | | 01/12/2032 | | | ||
| | | 01/12/2023 | | | | | | 0 | | | | | | 1,407,072 | | | | | | 0.53 | | | | | | 01/12/2032 | | |
Name
|
| |
First date some
or all options are exercisable(1) |
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable(2) |
| |
Number of
Securities Underlying Unexercised Options(#) Unexercisable(2) |
| |
Option
Exercise Price ($/Sh)(3) |
| |
Option
Expiration Date |
| |||||||||||||||
Elliot Norry
|
| | | | 01/18/2017(4) | | | | | | 200,000 | | | | | | 0 | | | | | | 1.08 | | | | | | 01/18/2026 | | |
| | | 01/13/2018(4) | | | | | | 63,024 | | | | | | 0 | | | | | | 0.71 | | | | | | 01/13/2027 | | | ||
| | | 07/07/2018(4) | | | | | | 300,000 | | | | | | 0 | | | | | | 0.75 | | | | | | 07/07/2027 | | | ||
| | | 01/12/2019(4) | | | | | | 79,824 | | | | | | 0 | | | | | | 1.16 | | | | | | 01/12/2028 | | | ||
| | | 01/04/2020 | | | | | | 0 | | | | | | 13,422 | | | | | | 0.0012 | | | | | | 01/04/2029 | | | ||
| | | 01/04/2020 | | | | | | 78,161 | | | | | | 1,663 | | | | | | 0.85 | | | | | | 01/04/2029 | | | ||
| | | 01/16/2021 | | | | | | 147,000 | | | | | | 54,600 | | | | | | 0.69 | | | | | | 01/16/2030 | | | ||
| | | 01/16/2021 | | | | | | 0 | | | | | | 67,800 | | | | | | 0.0012 | | | | | | 01/16/2030 | | | ||
| | | 01/11/2022 | | | | | | 520,766 | | | | | | 566,050 | | | | | | 0.92 | | | | | | 01/11/2031 | | | ||
| | | 01/11/2022 | | | | | | 0 | | | | | | 182,034 | | | | | | 0.0012 | | | | | | 01/11/2031 | | | ||
| | | 01/12/2023 | | | | | | 0 | | | | | | 471,360 | | | | | | 0.0012 | | | | | | 01/12/2032 | | | ||
| | | 01/12/2023 | | | | | | 0 | | | | | | 2,110,608 | | | | | | 0.53 | | | | | | 01/12/2032 | | | ||
Cintia Piccina
|
| | | | 01/31/2023 | | | | | | 0 | | | | | | 3,376,992 | | | | | | 0.40 | | | | | | 01/31/2032 | | |
| | | 01/31/2023 | | | | | | 0 | | | | | | 754,200 | | | | | | 0.0012 | | | | | | 01/31/2032 | | |
| | |
Option Awards
|
| |||||||||
Name
|
| |
Number of Shares
Acquired on Exercise (#)(1) |
| |
Value Realized on
Exercise ($)(2) |
| ||||||
Adrian Rawcliffe
|
| | | | 83,558 | | | | | | 273,278 | | |
Gavin Wood
|
| | | | — | | | | | | — | | |
William Bertrand
|
| | | | 37,182 | | | | | | 132,353 | | |
Elliot Norry
|
| | | | 20,237 | | | | | | 70,860 | | |
Cintia Piccina
|
| | | | 55,864 | | | | | | 98,666 | | |
Name
|
| |
Benefit(1)
|
| |
Termination
without Cause or Resignation for Good Reason Not in Connection with a Change in Control ($) |
| |
Termination
without Cause or Resignation for Good Reason in Connection with a Change in Control ($) |
| ||||||
Adrian Rawcliffe
|
| |
Lump Sum Cash Severance Payment
|
| | | | 487,500 | | | | | | 650,000 | | |
| Lump Sum Bonus Payment(2) | | | | | — | | | | | | — | | | ||
| Vesting Acceleration(3) | | | | | — | | | | | | 487,864 | | | ||
| Health Insurance Premiums(4) | | | | | 14,413 | | | | | | 19,217 | | | ||
| Benefit Total | | | | | 501,913 | | | | | | 1,157,081 | | | ||
Gavin Wood
|
| |
Lump Sum Cash Severance Payment
|
| | | | 314,714 | | | | | | 419,618 | | |
| Lump Sum Bonus Payment(2) | | | | | 56,648 | | | | | | 56,648 | | | ||
| Vesting Acceleration(3) | | | | | — | | | | | | 188,563 | | | ||
| Health Insurance Premiums(4) | | | | | 2,001 | | | | | | 2,668 | | | ||
| Benefit Total | | | | | 373,363 | | | | | | 667,497 | | | ||
William Bertrand
|
| |
Lump Sum Cash Severance Payment
|
| | | | 351,134 | | | | | | 468,179 | | |
| Lump Sum Bonus Payment(2) | | | | | 63,204 | | | | | | 63,204 | | | ||
| Vesting Acceleration(3) | | | | | — | | | | | | 167,772 | | | ||
| Health Insurance Premiums(4) | | | | | 18,621 | | | | | | 24,828 | | | ||
| Benefit Total | | | | | 432,959 | | | | | | 723,983 | | | ||
Elliot Norry
|
| |
Lump Sum Cash Severance Payment
|
| | | | 334,766 | | | | | | 446,355 | | |
| Lump Sum Bonus Payment(2) | | | | | 60,258 | | | | | | 60,258 | | | ||
| Vesting Acceleration(3) | | | | | — | | | | | |